Tag : iPSCs

Written on Dec, 11, 2019 by in

Thirty (30) years ago, exosomes were first described as extracellular vesicles (References 1 and 5). Extracellular vesicles (EVs) are cell derived membrane structures. They are secreted as a result of fusions between intracellular endosomes and the plasma membrane.  Alternatively, they are dispensed from the plasma membrane as microvesicles. Since their initial discovery, exosomes have become implicated in the mechanisms of intercellular signaling (aka. cell-to-cell signaling) and cell-to-cell maintenance of homeostasis. Since their initial discovery, EVs have gained much respect in the cell biology world. They are represented as an important mechanism of cell-to-cell communication — transferring cell membranes, cytosolic proteins, lipids, DNA, RNA, microRNA, etc.  (more…)

Tell us more...Continue Reading...
Written on Mar, 22, 2019 by in , ,

Welcome back to our cell of the month series. This time we’re talking about CD34+ cells, a type of undifferentiated multipotent hematopoetic stem cell (HSC) with the potential to differentiate into almost any other blood cell type under specific conditions. As stem cells, CD34+ cells naturally have the capacity for self-renewal, allowing them to divide and replicate indefinitely, making them a highly valuable source of hematopoetic cells in research and clinical settings. However, the CD34+ cell population in blood is extremely small, and is estimated to represent less than 0.5% of all other blood cell types.

(more…)

Tell us more...Continue Reading...
Written on Dec, 17, 2018 by in ,

The increasing complexity of novel therapies calls for disease models that take us closer than ever before to the in vivo situation, to maximize efficacy and safety evaluations of new experimental treatments. Significant improvements in our understanding of mammalian tissue development, homeostasis, and extracellular matrix biology, coupled with advances in human iPSCs (adult stem cells) and 3D culture have facilitated the generation of organoids and organ-on-a-chip technologies that serve as in vitro 3D models of healthy and diseased mammalian tissue. These technologies aim to become an integral part of research and drug discovery to provide novel insights into biological processes, mechanisms of disease, and responses to drug candidates and other treatments.

Tempo Bioscience attended the World Preclinical Congress Europe in Lisbon last month. This congress centers on preclinical research across a broad disease spectrum, and aims to illuminate the challenges and opportunities within early drug discovery and development. This years program covered topics spanning organ-on-a-chip, 3D cellular models, human induced pluripotent stem cells (hiPSC), and artificial intelligence and machine learning in drug discovery, to name a few. Of particular interest to Tempo Bioscience, the meeting highlighted progress as well as challenges with organs-on-chips, with the latter including scalability and adaption of the technology for applications in the biopharma industry. Here, we round up our top 3 symposium highlights within the organ-on-a-chip space.

(more…)

Tell us more...Continue Reading...